|Calculated MW||Calculated MW of 12.8 kDa with no tag. The predicted N-terminus is Asn49. DTT-reduced protein migrates as 16 kDa due to glycosylation.|
|Other Names||IL-15, IL15, Interleukin-15|
|Source||HEK 293 cells|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile deionized water to a concentration of 100 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in 20 mM Tris, 100 mM NaCl, pH 8.0. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Interleukin 15, also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus (es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x (L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health
Grabstein K.H.,et al.Science 264:965-968(1994).
Krause H.,et al.Cytokine 8:667-674(1996).
Meazza R.,et al.Oncogene 12:2187-2192(1996).
Tagaya Y.,et al.Proc. Natl. Acad. Sci. U.S.A. 94:14444-14449(1997).
Meazza R.,et al.Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
If you have any additional inquiries please email technical services at email@example.com.